logo
How Myles Downey is Transforming Leadership Performance Powered Through Strategic Coaching, Innovation, and Passion

How Myles Downey is Transforming Leadership Performance Powered Through Strategic Coaching, Innovation, and Passion

Myles Downey
Myles Downey, a veteran coach and author, has spent over four decades at the forefront of performance coaching, quietly shaping the leaders who shape industries. Based in Europe, Downey is recognised as a reputed leading business performance coach. His work has been strengthened by an unwavering mission of helping people unlock their innate potential, step into their unique genius, and succeed, not only for themselves, but for the organisations they lead.
"I've always been fascinated by helping people express themselves fully," Downey says. "I often feel this rage in me about how often people are suppressed by education, by rigid systems, by the stereotypes that dictate society. Coaching is my way of rebelling against that."
Born in Dublin, Downey's early years as a competitive tennis player taught him lessons that would be the catalyst for his life's work. Yet, his ultimate turning point came after reading The Inner Book of Tennis in the early 1970s. "It was revolutionary," he recalls. "The book helped me realise that in order to be self-expressed, you have to build trust in self. That I could learn without being taught in a traditional way."
This insight set him on a path from architecture in Dublin to London, where he trained directly in the "Inner Game" methodology and began translating those principles into business coaching.
After discovering that new approach, Downey's career quickly became a study in pioneering. In 1987, he was a part of The Alexander Corporation. Less than a decade later, he established The School of Coaching in 1996, which was arguably the first formal institution in the UK to offer professional coaching education.
"We wanted to move coaching from the shadows into a discipline that was both respected and practical," he explains. And it was this commitment to both rigour and results that has since defined his approach towards every one of his endeavours.
Downey reflected his influence through his books, which have become foundational texts in the coaching realm. Effective Coaching , first published in 1999 and now in its fourth edition as Effective Modern Coaching, has sold thousands of copies and is available worldwide. He later authored Enabling Genius , challenging the notion that brilliance is reserved for the rare few.
"The idea that only notable personalities like Einstein or Mozart could be geniuses is an outdated belief," Downey reflects. "Everyone has a unique genius. The work is to find it, embody it, and use it." And his 2022 release, The Enabling Manager , brings that philosophy to structural leadership, helping managers unlock the true potential within their teams.
Ultimately, through his books, Downey has sought to help readers access the embodiment of their potential, crafting tangible, workable strategies to help identify and train their genius.
Today, Downey's focus is redirected towards something intentional, something he calls 'leadership performance coaching.' Unlike traditional leadership development, which he views as overly abstract and often disconnected from results, leader performance, he believes, dives into real-world impact.
"My job is quite straightforward," he shares. "Help leaders in improving their performance. Performance first, development second. Once they've achieved clarity and purpose, growth follows naturally."
Downey's approach blends challenge with empathy. He has a deep respect for the pressures that today's leaders endure, balancing the short-term demands of shareholders with the long-term vitality of their people and organisations.
"Leaders operate in uncertainty a lot of the time," Downey explains. "An effective coach here has the responsibility to help them navigate that uncertainty, find clarity, and then act with intent. Once a leader is clear, that clarity cascades through their work, teams, and organisation."
Downey's work has made an impact on C-suites across continents, from Europe to America, to Asia, and spans industries from finance to media to public service. He has kept his craft at the forefront of his focus, instead of recognition or acclaim. "The thrill is in helping businesses bring an idea to life," he says. "Launching a bank, reshaping a business, unlocking someone's potential, those moments never get old."
Even as he continues to coach top executives, Downey is exploring new ways to share his insights. One being a novella, set in the Dublin pubs of his youth, where two strangers meet, and through a series of conversations, one steps into his own shoes as a leader. The book, while playful in design, reflects Downey's lifelong mission of helping people recognise and embrace their unique genius.
After a plethora of experiences in redefining leadership globally, Downey always returns to the belief that has guided him from the start: "Coaching is about giving people permission to be themselves," he says. "When leaders step into that space, where they are clear, authentic, and fully themselves, performance follows. And with it, transformation."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

Yahoo

time3 minutes ago

  • Yahoo

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So should INOVIQ (ASX:IIQ) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Long Is INOVIQ's Cash Runway? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at December 2024, INOVIQ had cash of AU$9.5m and no debt. Looking at the last year, the company burnt through AU$4.7m. That means it had a cash runway of about 2.0 years as of December 2024. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below. View our latest analysis for INOVIQ How Well Is INOVIQ Growing? On balance, we think it's mildly positive that INOVIQ trimmed its cash burn by 17% over the last twelve months. But the revenue dip of 17% in the same period was a bit concerning. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years. How Easily Can INOVIQ Raise Cash? Even though it seems like INOVIQ is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of AU$44m, INOVIQ's AU$4.7m in cash burn equates to about 11% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution. So, Should We Worry About INOVIQ's Cash Burn? Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought INOVIQ's cash runway was relatively promising. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about INOVIQ's situation. Taking a deeper dive, we've spotted 5 warning signs for INOVIQ you should be aware of, and 1 of them makes us a bit uncomfortable. Of course INOVIQ may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DEA Accountability as Cannabis Research Crisis Deepens And Patients Suffer
DEA Accountability as Cannabis Research Crisis Deepens And Patients Suffer

Yahoo

time3 minutes ago

  • Yahoo

DEA Accountability as Cannabis Research Crisis Deepens And Patients Suffer

With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. MMJ International Holdings Issues Clarification on Irvine Labs. WASHINGTON, DC / / August 1, 2025 / MMJ International Holdings, Inc. ("MMJ") today issued a public clarification regarding prior statements about Irvine Labs, Inc., while calling for an urgent reckoning with the U.S. Drug Enforcement Administration's (DEA) catastrophic mismanagement of America's cannabis research policy. In a previous press release, MMJ referenced widespread inactivity among DEA-registered marijuana manufacturers. While these statements were intended to highlight systemic failures within the DEA's quota and licensing system, MMJ acknowledges that this language may have unintentionally caused confusion regarding Irvine Labs, Inc. MMJ hereby clarifies that Irvine Labs, Inc. is a registered DEA entity and, to the best of MMJ's current knowledge, holds valid DEA registrations. MMJ did not intend to imply that Irvine Labs is inactive or insolvent, and any interpretation suggesting otherwise is hereby retracted. This clarification, however, does not alter the underlying crisis: the DEA's marijuana manufacturing quota system is fundamentally broken. Despite a supposed expansion of DEA licenses, no registrant-except MMJ-has produced sufficient pharmaceutical-grade cannabis to support a single FDA-compliant clinical trial. The Devastating Reality: Maridose (Maine): Only 1,100 sq. ft. of space, not growing. Bright Green Corp: Surrendered its registration without ever planting a crop. Royal Emerald Pharmaceuticals: Inactive and facing financial distress. Groff NA Hemplex & Scottsdale Research Institute: No active cultivation for clinical trials. BRC: Producing quantities far below clinical thresholds. University of Mississippi: Continues to grow substandard, research-incompatible marijuana. MMJ remains the only federally compliant entity actively pursuing the cultivation of strain-specific, pharmaceutical-grade cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. Yet, for over seven years, the DEA has obstructed MMJ's efforts through unconstitutional administrative proceedings, arbitrary quotas, and a bureaucratic "Catch-22" that demands documentation (BFSA) which is unattainable without the very registration the DEA refuses to grant. A Constitutional Crisis Exposed The Supreme Court's rulings in Axon v. FTC and Jarkesy v. SEC have now exposed the DEA's internal administrative law judge (ALJ) system as an unconstitutional charade. Despite this, DEA legal counsel Aarathi Haig continues to defend a system the Department of Justice has now abandoned. Former Chief ALJ John "McLooney" Mulrooney has since retired, leaving behind what critics call a "legal dumpster fire." MMJ's legal exceptions, filed July 3, 2025, detail the agency's structural bias, retroactive sabotage, and deliberate obstruction of medical research. "We followed every law, built the FDA-inspected facility, and secured our clinical approvals," said Duane Boise, CEO of MMJ International Holdings. "What the DEA calls regulation is nothing more than bureaucratic revenge." The Time for Reckoning is Now With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. This demands immediate action: Fire entrenched obstructionists like Thomas Prevoznik. Investigate Aarathi Haig for perpetuating unconstitutional legal processes. Transfer oversight of cannabis research to the FDA, where science-not sabotage-will guide policy. "The DEA has spent a decade fortifying a broken system that protects monopolies, obstructs innovation, and ignores public safety disasters like the Assured Testing Labs scandal in Massachusetts," said Boise. "America doesn't need another anti-marijuana crooner in a suit-it needs a leader who will stand up to this agency's sabotage and put patients first." MMJ International Holdings remains committed to factual accuracy and will continue to expose systemic failures that endanger patients, stifle science, and betray the public trust. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store